aluates Reports

$ 0.0

Automative

Global Pharmaceutical CDMO Market Research Report 2026

Published Date: 2026-04-20

Report Code: QYRE-Auto-39T13723

Global Pharmaceutical CDMO Market Research Report 2023

BUY CHAPTERS

Global Pharmaceutical CDMO Market Research Report 2026

Code: QYRE-Auto-39T13723

Report

2026-04-20

Pages:174

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Lonza

Catalent

Thermo Fisher Scientific

Samsung Biologics

Fareva

WuXi AppTech

Wuxi Biologics

Siegfried

FUJIFILM Diosynth Biotechnologies

Asymchem

Pfizer CentreOne

Delpharm

Recipharm

AGC Pharma Chemicals

Boehringer Ingelheim

Vetter

Curia

Aenova

Porton

Piramal

Strides Pharma

NextPharma

Famar

Jubilant

Alcami

EUROAPI

Eurofins

Avid Bioservices

BioVectra

CPL

Pharmaceutical CDMO Market Size

The global Pharmaceutical CDMO market was valued at US$ 159270 million in 2025 and is anticipated to reach US$ 265450 million by 2032, at a CAGR of 7.7% from 2026 to 2032.

Pharmaceutical CDMO Market

A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.

Contract Pharmaceutical Manufacturing is part of CDMO, refers to accept commissioned from pharmaceutical companies, provide the service about API production, FDF production, packaging.

Pharmaceutical companies are likely to outsource a wide range of manufacturing related activities including – primary and secondary packaging, formulation, active ingredient manufacturing, labeling, clinical supplies, sterilization, manufacturing of chemical intermediates, etc. CDMOs support pharmaceutical companies at all stages of the process of making medicines: by providing services in the research and development stages, by offering support in manufacturing, and by providing formulating and finishing processes.

The key service providers of the Pharmaceutical CDMO in the world are Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among which the market share of the top three service providers exceeds 10%, and Lonza is the largest service provider. The services provided by global pharmaceutical CDMO are mainly distributed in North America, Europe and China, among which the top three regions account for nearly 60% of the market share, and North America is currently the largest service provider. In terms of its service type, the growth rate of FDF CDMO is relatively fast. At present, the market share of API CDMO is the highest, more than 40%, followed by FDF CDMO, packaging CDMO and clinical CDMO. In terms of its application, pharmaceutical company are the largest application field, with a market share of more than 60%, followed by biotechnology company.

This report delivers a comprehensive overview of the global Pharmaceutical CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pharmaceutical CDMO. The Pharmaceutical CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Pharmaceutical CDMO market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Pharmaceutical CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Pharmaceutical CDMO Market Report

Report Metric	Details
Report Name	Pharmaceutical CDMO Market
Accounted market size in 2025	US$ 159270 million
Forecasted market size in 2032	US$ 265450 million
CAGR	7.7%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	API CDMO FDF CDMO Packaging CDMO Clinical CDMO
Segment by Application	Pharmaceutical Company Biotechnology Company Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried, FUJIFILM Diosynth Biotechnologies, Asymchem, Pfizer CentreOne, Delpharm, Recipharm, AGC Pharma Chemicals, Boehringer Ingelheim, Vetter, Curia, Aenova, Porton, Piramal, Strides Pharma, NextPharma, Famar, Jubilant, Alcami, Euroapi, Eurofins, Avid Bioservices, BioVectra, CPL
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Pharmaceutical CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Pharmaceutical CDMO Market growing?

Ans: The Pharmaceutical CDMO Market witnessing a CAGR of 7.7% during the forecast period 2026-2032.

What is the Pharmaceutical CDMO Market size in 2032?

Ans: The Pharmaceutical CDMO Market size in 2032 will be US$ 265450 million.

What is the market share of major companies in Pharmaceutical CDMO Market?

Ans: The key service providers of the Pharmaceutical CDMO in the world are Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among which the market share of the top three service providers exceeds 10%, and Lonza is the largest service provider.

What is the Pharmaceutical CDMO Market share by region?

Ans: The services provided by global pharmaceutical CDMO are mainly distributed in North America, Europe and China, among which the top three regions account for nearly 60% of the market share, and North America is currently the largest service provider.

Who are the main players in the Pharmaceutical CDMO Market report?

Ans: The main players in the Pharmaceutical CDMO Market are Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried, FUJIFILM Diosynth Biotechnologies, Asymchem, Pfizer CentreOne, Delpharm, Recipharm, AGC Pharma Chemicals, Boehringer Ingelheim, Vetter, Curia, Aenova, Porton, Piramal, Strides Pharma, NextPharma, Famar, Jubilant, Alcami, Euroapi, Eurofins, Avid Bioservices, BioVectra, CPL

What are the Application segmentation covered in the Pharmaceutical CDMO Market report?

Ans: The Applications covered in the Pharmaceutical CDMO Market report are Pharmaceutical Company, Biotechnology Company, Other

What are the Type segmentation covered in the Pharmaceutical CDMO Market report?

Ans: The Types covered in the Pharmaceutical CDMO Market report are API CDMO, FDF CDMO, Packaging CDMO, Clinical CDMO

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Pharmaceutical CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 API CDMO

1.2.3 FDF CDMO

1.2.4 Packaging CDMO

1.2.5 Clinical CDMO

1.3 Market by Application

1.3.1 Global Pharmaceutical CDMO Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Pharmaceutical Company

1.3.3 Biotechnology Company

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Pharmaceutical CDMO Market Perspective (2021–2032)

2.2 Global Pharmaceutical CDMO Growth Trends by Region

2.2.1 Global Pharmaceutical CDMO Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Pharmaceutical CDMO Historic Market Size by Region (2021–2026)

2.2.3 Pharmaceutical CDMO Forecasted Market Size by Region (2027–2032)

2.3 Pharmaceutical CDMO Market Dynamics

2.3.1 Pharmaceutical CDMO Industry Trends

2.3.2 Pharmaceutical CDMO Market Drivers

2.3.3 Pharmaceutical CDMO Market Challenges

2.3.4 Pharmaceutical CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Pharmaceutical CDMO Players by Revenue

3.1.1 Global Top Pharmaceutical CDMO Players by Revenue (2021–2026)

3.1.2 Global Pharmaceutical CDMO Revenue Market Share by Players (2021–2026)

3.2 Global Top Pharmaceutical CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Pharmaceutical CDMO Revenue

3.4 Global Pharmaceutical CDMO Market Concentration Ratio

3.4.1 Global Pharmaceutical CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical CDMO Revenue in 2025

3.5 Global Key Players of Pharmaceutical CDMO Head Offices and Areas Served

3.6 Global Key Players of Pharmaceutical CDMO, Products and Applications

3.7 Global Key Players of Pharmaceutical CDMO, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Pharmaceutical CDMO Breakdown Data by Type

4.1 Global Pharmaceutical CDMO Historic Market Size by Type (2021–2026)

4.2 Global Pharmaceutical CDMO Forecasted Market Size by Type (2027–2032)

5 Pharmaceutical CDMO Breakdown Data by Application

5.1 Global Pharmaceutical CDMO Historic Market Size by Application (2021–2026)

5.2 Global Pharmaceutical CDMO Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Pharmaceutical CDMO Market Size (2021–2032)

6.2 North America Pharmaceutical CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Pharmaceutical CDMO Market Size by Country (2021–2026)

6.4 North America Pharmaceutical CDMO Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Pharmaceutical CDMO Market Size (2021–2032)

7.2 Europe Pharmaceutical CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Pharmaceutical CDMO Market Size by Country (2021–2026)

7.4 Europe Pharmaceutical CDMO Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Pharmaceutical CDMO Market Size (2021–2032)

8.2 Asia-Pacific Pharmaceutical CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Pharmaceutical CDMO Market Size by Region (2021–2026)

8.4 Asia-Pacific Pharmaceutical CDMO Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Pharmaceutical CDMO Market Size (2021–2032)

9.2 Latin America Pharmaceutical CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Pharmaceutical CDMO Market Size by Country (2021–2026)

9.4 Latin America Pharmaceutical CDMO Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Pharmaceutical CDMO Market Size (2021–2032)

10.2 Middle East & Africa Pharmaceutical CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Pharmaceutical CDMO Market Size by Country (2021–2026)

10.4 Middle East & Africa Pharmaceutical CDMO Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Lonza

11.1.1 Lonza Company Details

11.1.2 Lonza Business Overview

11.1.3 Lonza Pharmaceutical CDMO Introduction

11.1.4 Lonza Revenue in Pharmaceutical CDMO Business (2021–2026)

11.1.5 Lonza Recent Development

11.2 Catalent

11.2.1 Catalent Company Details

11.2.2 Catalent Business Overview

11.2.3 Catalent Pharmaceutical CDMO Introduction

11.2.4 Catalent Revenue in Pharmaceutical CDMO Business (2021–2026)

11.2.5 Catalent Recent Development

11.3 Thermo Fisher Scientific

11.3.1 Thermo Fisher Scientific Company Details

11.3.2 Thermo Fisher Scientific Business Overview

11.3.3 Thermo Fisher Scientific Pharmaceutical CDMO Introduction

11.3.4 Thermo Fisher Scientific Revenue in Pharmaceutical CDMO Business (2021–2026)

11.3.5 Thermo Fisher Scientific Recent Development

11.4 Samsung Biologics

11.4.1 Samsung Biologics Company Details

11.4.2 Samsung Biologics Business Overview

11.4.3 Samsung Biologics Pharmaceutical CDMO Introduction

11.4.4 Samsung Biologics Revenue in Pharmaceutical CDMO Business (2021–2026)

11.4.5 Samsung Biologics Recent Development

11.5 Fareva

11.5.1 Fareva Company Details

11.5.2 Fareva Business Overview

11.5.3 Fareva Pharmaceutical CDMO Introduction

11.5.4 Fareva Revenue in Pharmaceutical CDMO Business (2021–2026)

11.5.5 Fareva Recent Development

11.6 WuXi AppTech

11.6.1 WuXi AppTech Company Details

11.6.2 WuXi AppTech Business Overview

11.6.3 WuXi AppTech Pharmaceutical CDMO Introduction

11.6.4 WuXi AppTech Revenue in Pharmaceutical CDMO Business (2021–2026)

11.6.5 WuXi AppTech Recent Development

11.7 WuXi Biologics

11.7.1 WuXi Biologics Company Details

11.7.2 WuXi Biologics Business Overview

11.7.3 WuXi Biologics Pharmaceutical CDMO Introduction

11.7.4 WuXi Biologics Revenue in Pharmaceutical CDMO Business (2021–2026)

11.7.5 WuXi Biologics Recent Development

11.8 Siegfried

11.8.1 Siegfried Company Details

11.8.2 Siegfried Business Overview

11.8.3 Siegfried Pharmaceutical CDMO Introduction

11.8.4 Siegfried Revenue in Pharmaceutical CDMO Business (2021–2026)

11.8.5 Siegfried Recent Development

11.9 FUJIFILM Diosynth Biotechnologies

11.9.1 FUJIFILM Diosynth Biotechnologies Company Details

11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview

11.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Introduction

11.9.4 FUJIFILM Diosynth Biotechnologies Revenue in Pharmaceutical CDMO Business (2021–2026)

11.9.5 FUJIFILM Diosynth Biotechnologies Recent Development

11.10 Asymchem

11.10.1 Asymchem Company Details

11.10.2 Asymchem Business Overview

11.10.3 Asymchem Pharmaceutical CDMO Introduction

11.10.4 Asymchem Revenue in Pharmaceutical CDMO Business (2021–2026)

11.10.5 Asymchem Recent Development

11.11 Pfizer CentreOne

11.11.1 Pfizer CentreOne Company Details

11.11.2 Pfizer CentreOne Business Overview

11.11.3 Pfizer CentreOne Pharmaceutical CDMO Introduction

11.11.4 Pfizer CentreOne Revenue in Pharmaceutical CDMO Business (2021–2026)

11.11.5 Pfizer CentreOne Recent Development

11.12 Delpharm

11.12.1 Delpharm Company Details

11.12.2 Delpharm Business Overview

11.12.3 Delpharm Pharmaceutical CDMO Introduction

11.12.4 Delpharm Revenue in Pharmaceutical CDMO Business (2021–2026)

11.12.5 Delpharm Recent Development

11.13 Recipharm

11.13.1 Recipharm Company Details

11.13.2 Recipharm Business Overview

11.13.3 Recipharm Pharmaceutical CDMO Introduction

11.13.4 Recipharm Revenue in Pharmaceutical CDMO Business (2021–2026)

11.13.5 Recipharm Recent Development

11.14 AGC Pharma Chemicals

11.14.1 AGC Pharma Chemicals Company Details

11.14.2 AGC Pharma Chemicals Business Overview

11.14.3 AGC Pharma Chemicals Pharmaceutical CDMO Introduction

11.14.4 AGC Pharma Chemicals Revenue in Pharmaceutical CDMO Business (2021–2026)

11.14.5 AGC Pharma Chemicals Recent Development

11.15 Boehringer Ingelheim

11.15.1 Boehringer Ingelheim Company Details

11.15.2 Boehringer Ingelheim Business Overview

11.15.3 Boehringer Ingelheim Pharmaceutical CDMO Introduction

11.15.4 Boehringer Ingelheim Revenue in Pharmaceutical CDMO Business (2021–2026)

11.15.5 Boehringer Ingelheim Recent Development

11.16 Vetter

11.16.1 Vetter Company Details

11.16.2 Vetter Business Overview

11.16.3 Vetter Pharmaceutical CDMO Introduction

11.16.4 Vetter Revenue in Pharmaceutical CDMO Business (2021–2026)

11.16.5 Vetter Recent Development

11.17 Curia

11.17.1 Curia Company Details

11.17.2 Curia Business Overview

11.17.3 Curia Pharmaceutical CDMO Introduction

11.17.4 Curia Revenue in Pharmaceutical CDMO Business (2021–2026)

11.17.5 Curia Recent Development

11.18 Aenova

11.18.1 Aenova Company Details

11.18.2 Aenova Business Overview

11.18.3 Aenova Pharmaceutical CDMO Introduction

11.18.4 Aenova Revenue in Pharmaceutical CDMO Business (2021–2026)

11.18.5 Aenova Recent Development

11.19 Porton

11.19.1 Porton Company Details

11.19.2 Porton Business Overview

11.19.3 Porton Pharmaceutical CDMO Introduction

11.19.4 Porton Revenue in Pharmaceutical CDMO Business (2021–2026)

11.19.5 Porton Recent Development

11.20 Piramal

11.20.1 Piramal Company Details

11.20.2 Piramal Business Overview

11.20.3 Piramal Pharmaceutical CDMO Introduction

11.20.4 Piramal Revenue in Pharmaceutical CDMO Business (2021–2026)

11.20.5 Piramal Recent Development

11.21 Strides Pharma

11.21.1 Strides Pharma Company Details

11.21.2 Strides Pharma Business Overview

11.21.3 Strides Pharma Pharmaceutical CDMO Introduction

11.21.4 Strides Pharma Revenue in Pharmaceutical CDMO Business (2021–2026)

11.21.5 Strides Pharma Recent Development

11.22 NextPharma

11.22.1 NextPharma Company Details

11.22.2 NextPharma Business Overview

11.22.3 NextPharma Pharmaceutical CDMO Introduction

11.22.4 NextPharma Revenue in Pharmaceutical CDMO Business (2021–2026)

11.22.5 NextPharma Recent Development

11.23 Famar

11.23.1 Famar Company Details

11.23.2 Famar Business Overview

11.23.3 Famar Pharmaceutical CDMO Introduction

11.23.4 Famar Revenue in Pharmaceutical CDMO Business (2021–2026)

11.23.5 Famar Recent Development

11.24 Jubilant

11.24.1 Jubilant Company Details

11.24.2 Jubilant Business Overview

11.24.3 Jubilant Pharmaceutical CDMO Introduction

11.24.4 Jubilant Revenue in Pharmaceutical CDMO Business (2021–2026)

11.24.5 Jubilant Recent Development

11.25 Alcami

11.25.1 Alcami Company Details

11.25.2 Alcami Business Overview

11.25.3 Alcami Pharmaceutical CDMO Introduction

11.25.4 Alcami Revenue in Pharmaceutical CDMO Business (2021–2026)

11.25.5 Alcami Recent Development

11.26 Euroapi

11.26.1 Euroapi Company Details

11.26.2 Euroapi Business Overview

11.26.3 Euroapi Pharmaceutical CDMO Introduction

11.26.4 Euroapi Revenue in Pharmaceutical CDMO Business (2021–2026)

11.26.5 Euroapi Recent Development

11.27 Eurofins

11.27.1 Eurofins Company Details

11.27.2 Eurofins Business Overview

11.27.3 Eurofins Pharmaceutical CDMO Introduction

11.27.4 Eurofins Revenue in Pharmaceutical CDMO Business (2021–2026)

11.27.5 Eurofins Recent Development

11.28 Avid Bioservices

11.28.1 Avid Bioservices Company Details

11.28.2 Avid Bioservices Business Overview

11.28.3 Avid Bioservices Pharmaceutical CDMO Introduction

11.28.4 Avid Bioservices Revenue in Pharmaceutical CDMO Business (2021–2026)

11.28.5 Avid Bioservices Recent Development

11.29 BioVectra

11.29.1 BioVectra Company Details

11.29.2 BioVectra Business Overview

11.29.3 BioVectra Pharmaceutical CDMO Introduction

11.29.4 BioVectra Revenue in Pharmaceutical CDMO Business (2021–2026)

11.29.5 BioVectra Recent Development

11.30 CPL

11.30.1 CPL Company Details

11.30.2 CPL Business Overview

11.30.3 CPL Pharmaceutical CDMO Introduction

11.30.4 CPL Revenue in Pharmaceutical CDMO Business (2021–2026)

11.30.5 CPL Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Lonza

Catalent

Thermo Fisher Scientific

Samsung Biologics

Fareva

WuXi AppTech

Wuxi Biologics

Siegfried

FUJIFILM Diosynth Biotechnologies

Asymchem

Pfizer CentreOne

Delpharm

Recipharm

AGC Pharma Chemicals

Boehringer Ingelheim

Vetter

Curia

Aenova

Porton

Piramal

Strides Pharma

NextPharma

Famar

Jubilant

Alcami

EUROAPI

Eurofins

Avid Bioservices

BioVectra

CPL

List of Tables

Table 1. Global Pharmaceutical CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of API CDMO

Table 3. Key Players of FDF CDMO

Table 4. Key Players of Packaging CDMO

Table 5. Key Players of Clinical CDMO

Table 6. Global Pharmaceutical CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global Pharmaceutical CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 8. Global Pharmaceutical CDMO Market Size by Region (US$ Million), 2021–2026

Table 9. Global Pharmaceutical CDMO Market Share by Region (2021–2026)

Table 10. Global Pharmaceutical CDMO Forecasted Market Size by Region (US$ Million), 2027–2032

Table 11. Global Pharmaceutical CDMO Market Share by Region (2027–2032)

Table 12. Pharmaceutical CDMO Market Trends

Table 13. Pharmaceutical CDMO Market Drivers

Table 14. Pharmaceutical CDMO Market Challenges

Table 15. Pharmaceutical CDMO Market Restraints

Table 16. Global Pharmaceutical CDMO Revenue by Players (US$ Million), 2021–2026

Table 17. Global Pharmaceutical CDMO Market Share by Players (2021–2026)

Table 18. Global Top Pharmaceutical CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Pharmaceutical CDMO Revenue, 2025

Table 19. Ranking of Global Top Pharmaceutical CDMO Companies by Revenue (US$ Million) in 2025

Table 20. Global 5 Largest Players Market Share by Pharmaceutical CDMO Revenue (CR5 and HHI), 2021–2026

Table 21. Global Key Players of Pharmaceutical CDMO, Headquarters and Area Served

Table 22. Global Key Players of Pharmaceutical CDMO, Products and Applications

Table 23. Global Key Players of Pharmaceutical CDMO, Date of General Availability (GA)

Table 24. Mergers and Acquisitions, Expansion Plans

Table 25. Global Pharmaceutical CDMO Market Size by Type (US$ Million), 2021–2026

Table 26. Global Pharmaceutical CDMO Revenue Market Share by Type (2021–2026)

Table 27. Global Pharmaceutical CDMO Forecasted Market Size by Type (US$ Million), 2027–2032

Table 28. Global Pharmaceutical CDMO Revenue Market Share by Type (2027–2032)

Table 29. Global Pharmaceutical CDMO Market Size by Application (US$ Million), 2021–2026

Table 30. Global Pharmaceutical CDMO Revenue Market Share by Application (2021–2026)

Table 31. Global Pharmaceutical CDMO Forecasted Market Size by Application (US$ Million), 2027–2032

Table 32. Global Pharmaceutical CDMO Revenue Market Share by Application (2027–2032)

Table 33. North America Pharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 34. North America Pharmaceutical CDMO Market Size by Country (US$ Million), 2021–2026

Table 35. North America Pharmaceutical CDMO Market Size by Country (US$ Million), 2027–2032

Table 36. Europe Pharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 37. Europe Pharmaceutical CDMO Market Size by Country (US$ Million), 2021–2026

Table 38. Europe Pharmaceutical CDMO Market Size by Country (US$ Million), 2027–2032

Table 39. Asia-Pacific Pharmaceutical CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 40. Asia-Pacific Pharmaceutical CDMO Market Size by Region (US$ Million), 2021–2026

Table 41. Asia-Pacific Pharmaceutical CDMO Market Size by Region (US$ Million), 2027–2032

Table 42. Latin America Pharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 43. Latin America Pharmaceutical CDMO Market Size by Country (US$ Million), 2021–2026

Table 44. Latin America Pharmaceutical CDMO Market Size by Country (US$ Million), 2027–2032

Table 45. Middle East & Africa Pharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 46. Middle East & Africa Pharmaceutical CDMO Market Size by Country (US$ Million), 2021–2026

Table 47. Middle East & Africa Pharmaceutical CDMO Market Size by Country (US$ Million), 2027–2032

Table 48. Lonza Company Details

Table 49. Lonza Business Overview

Table 50. Lonza Pharmaceutical CDMO Product

Table 51. Lonza Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 52. Lonza Recent Development

Table 53. Catalent Company Details

Table 54. Catalent Business Overview

Table 55. Catalent Pharmaceutical CDMO Product

Table 56. Catalent Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 57. Catalent Recent Development

Table 58. Thermo Fisher Scientific Company Details

Table 59. Thermo Fisher Scientific Business Overview

Table 60. Thermo Fisher Scientific Pharmaceutical CDMO Product

Table 61. Thermo Fisher Scientific Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 62. Thermo Fisher Scientific Recent Development

Table 63. Samsung Biologics Company Details

Table 64. Samsung Biologics Business Overview

Table 65. Samsung Biologics Pharmaceutical CDMO Product

Table 66. Samsung Biologics Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 67. Samsung Biologics Recent Development

Table 68. Fareva Company Details

Table 69. Fareva Business Overview

Table 70. Fareva Pharmaceutical CDMO Product

Table 71. Fareva Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 72. Fareva Recent Development

Table 73. WuXi AppTech Company Details

Table 74. WuXi AppTech Business Overview

Table 75. WuXi AppTech Pharmaceutical CDMO Product

Table 76. WuXi AppTech Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 77. WuXi AppTech Recent Development

Table 78. WuXi Biologics Company Details

Table 79. WuXi Biologics Business Overview

Table 80. WuXi Biologics Pharmaceutical CDMO Product

Table 81. WuXi Biologics Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 82. WuXi Biologics Recent Development

Table 83. Siegfried Company Details

Table 84. Siegfried Business Overview

Table 85. Siegfried Pharmaceutical CDMO Product

Table 86. Siegfried Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 87. Siegfried Recent Development

Table 88. FUJIFILM Diosynth Biotechnologies Company Details

Table 89. FUJIFILM Diosynth Biotechnologies Business Overview

Table 90. FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Product

Table 91. FUJIFILM Diosynth Biotechnologies Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 92. FUJIFILM Diosynth Biotechnologies Recent Development

Table 93. Asymchem Company Details

Table 94. Asymchem Business Overview

Table 95. Asymchem Pharmaceutical CDMO Product

Table 96. Asymchem Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 97. Asymchem Recent Development

Table 98. Pfizer CentreOne Company Details

Table 99. Pfizer CentreOne Business Overview

Table 100. Pfizer CentreOne Pharmaceutical CDMO Product

Table 101. Pfizer CentreOne Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 102. Pfizer CentreOne Recent Development

Table 103. Delpharm Company Details

Table 104. Delpharm Business Overview

Table 105. Delpharm Pharmaceutical CDMO Product

Table 106. Delpharm Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 107. Delpharm Recent Development

Table 108. Recipharm Company Details

Table 109. Recipharm Business Overview

Table 110. Recipharm Pharmaceutical CDMO Product

Table 111. Recipharm Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 112. Recipharm Recent Development

Table 113. AGC Pharma Chemicals Company Details

Table 114. AGC Pharma Chemicals Business Overview

Table 115. AGC Pharma Chemicals Pharmaceutical CDMO Product

Table 116. AGC Pharma Chemicals Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 117. AGC Pharma Chemicals Recent Development

Table 118. Boehringer Ingelheim Company Details

Table 119. Boehringer Ingelheim Business Overview

Table 120. Boehringer Ingelheim Pharmaceutical CDMO Product

Table 121. Boehringer Ingelheim Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 122. Boehringer Ingelheim Recent Development

Table 123. Vetter Company Details

Table 124. Vetter Business Overview

Table 125. Vetter Pharmaceutical CDMO Product

Table 126. Vetter Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 127. Vetter Recent Development

Table 128. Curia Company Details

Table 129. Curia Business Overview

Table 130. Curia Pharmaceutical CDMO Product

Table 131. Curia Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 132. Curia Recent Development

Table 133. Aenova Company Details

Table 134. Aenova Business Overview

Table 135. Aenova Pharmaceutical CDMO Product

Table 136. Aenova Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 137. Aenova Recent Development

Table 138. Porton Company Details

Table 139. Porton Business Overview

Table 140. Porton Pharmaceutical CDMO Product

Table 141. Porton Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 142. Porton Recent Development

Table 143. Piramal Company Details

Table 144. Piramal Business Overview

Table 145. Piramal Pharmaceutical CDMO Product

Table 146. Piramal Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 147. Piramal Recent Development

Table 148. Strides Pharma Company Details

Table 149. Strides Pharma Business Overview

Table 150. Strides Pharma Pharmaceutical CDMO Product

Table 151. Strides Pharma Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 152. Strides Pharma Recent Development

Table 153. NextPharma Company Details

Table 154. NextPharma Business Overview

Table 155. NextPharma Pharmaceutical CDMO Product

Table 156. NextPharma Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 157. NextPharma Recent Development

Table 158. Famar Company Details

Table 159. Famar Business Overview

Table 160. Famar Pharmaceutical CDMO Product

Table 161. Famar Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 162. Famar Recent Development

Table 163. Jubilant Company Details

Table 164. Jubilant Business Overview

Table 165. Jubilant Pharmaceutical CDMO Product

Table 166. Jubilant Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 167. Jubilant Recent Development

Table 168. Alcami Company Details

Table 169. Alcami Business Overview

Table 170. Alcami Pharmaceutical CDMO Product

Table 171. Alcami Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 172. Alcami Recent Development

Table 173. Euroapi Company Details

Table 174. Euroapi Business Overview

Table 175. Euroapi Pharmaceutical CDMO Product

Table 176. Euroapi Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 177. Euroapi Recent Development

Table 178. Eurofins Company Details

Table 179. Eurofins Business Overview

Table 180. Eurofins Pharmaceutical CDMO Product

Table 181. Eurofins Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 182. Eurofins Recent Development

Table 183. Avid Bioservices Company Details

Table 184. Avid Bioservices Business Overview

Table 185. Avid Bioservices Pharmaceutical CDMO Product

Table 186. Avid Bioservices Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 187. Avid Bioservices Recent Development

Table 188. BioVectra Company Details

Table 189. BioVectra Business Overview

Table 190. BioVectra Pharmaceutical CDMO Product

Table 191. BioVectra Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 192. BioVectra Recent Development

Table 193. CPL Company Details

Table 194. CPL Business Overview

Table 195. CPL Pharmaceutical CDMO Product

Table 196. CPL Revenue in Pharmaceutical CDMO Business (US$ Million), 2021–2026

Table 197. CPL Recent Development

Table 198. Research Programs/Design for This Report

Table 199. Key Data Information from Secondary Sources

Table 200. Key Data Information from Primary Sources

Table 201. Authors List of This Report

List of Figures

Figure 1. Pharmaceutical CDMO Picture

Figure 2. Global Pharmaceutical CDMO Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Pharmaceutical CDMO Market Share by Type: 2025 vs 2032

Figure 4. API CDMO Features

Figure 5. FDF CDMO Features

Figure 6. Packaging CDMO Features

Figure 7. Clinical CDMO Features

Figure 8. Global Pharmaceutical CDMO Market Size by Application (US$ Million), 2021–2032

Figure 9. Global Pharmaceutical CDMO Market Share by Application: 2025 vs 2032

Figure 10. Pharmaceutical Company Case Studies

Figure 11. Biotechnology Company Case Studies

Figure 12. Other Case Studies

Figure 13. Pharmaceutical CDMO Report Years Considered

Figure 14. Global Pharmaceutical CDMO Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 15. Global Pharmaceutical CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 16. Global Pharmaceutical CDMO Market Share by Region: 2025 vs 2032

Figure 17. Global Pharmaceutical CDMO Market Share by Players in 2025

Figure 18. Global Pharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 19. The Top 10 and 5 Players Market Share by Pharmaceutical CDMO Revenue in 2025

Figure 20. North America Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 21. North America Pharmaceutical CDMO Market Share by Country (2021–2032)

Figure 22. United States Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Canada Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Europe Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. Europe Pharmaceutical CDMO Market Share by Country (2021–2032)

Figure 26. Germany Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. France Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. U.K. Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Italy Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Russia Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Ireland Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Asia-Pacific Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Asia-Pacific Pharmaceutical CDMO Market Share by Region (2021–2032)

Figure 34. China Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Japan Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. South Korea Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Southeast Asia Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. India Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Australia & New Zealand Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Latin America Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Latin America Pharmaceutical CDMO Market Share by Country (2021–2032)

Figure 42. Mexico Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Brazil Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Middle East & Africa Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Middle East & Africa Pharmaceutical CDMO Market Share by Country (2021–2032)

Figure 46. Israel Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Saudi Arabia Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. UAE Pharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Lonza Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 50. Catalent Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 51. Thermo Fisher Scientific Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 52. Samsung Biologics Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 53. Fareva Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 54. WuXi AppTech Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 55. WuXi Biologics Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 56. Siegfried Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 57. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 58. Asymchem Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 59. Pfizer CentreOne Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 60. Delpharm Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 61. Recipharm Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 62. AGC Pharma Chemicals Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 63. Boehringer Ingelheim Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 64. Vetter Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 65. Curia Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 66. Aenova Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 67. Porton Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 68. Piramal Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 69. Strides Pharma Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 70. NextPharma Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 71. Famar Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 72. Jubilant Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 73. Alcami Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 74. Euroapi Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 75. Eurofins Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 76. Avid Bioservices Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 77. BioVectra Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 78. CPL Revenue Growth Rate in Pharmaceutical CDMO Business (2021–2026)

Figure 79. Bottom-up and Top-down Approaches for This Report

Figure 80. Data Triangulation

Figure 81. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Small Molecule Drug CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Pharmaceutical Contract Development and Manufacturing Organization Market Research Report 2025

Global Full Service CDMO Market Research Report 2024

Global Chemical Drug CDMO Market Research Report 2024

Global Chemical CDMO Market Research Report 2024

Global Formulation CDMO Services Market Research Report 2024

Global Contract Dose Manufacturing Market Insights Forecast to 2030

Pharmaceutical CDMO Solution Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Pharmaceutical CDMO Services Market

Global Biopharmaceutical CDMO Market Research Report 2025

Active Pharmaceutical Ingredients API CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Biopharmaceutical CDMO Service Market Research Report 2024

Global Small Molecule Drug CDMO Services Market Research Report 2024

Global Biopharmaceutical and Bio CDMO Market Research Report 2024

Active Pharmaceutical Ingredients CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antibody Drug CDMO Service Market Research Report 2024

Global Biological Drug CDMO Market Research Report 2024

Global Bio Contract Development and Manufacturing Organizations CDMOs Market Insights Forecast to 2030

Global Topical Drugs CDMO Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions